{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124546","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.858903+00:00","generated_at":"2026-05-30T01:54:28.008970+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome Q3 revenue $104.8M (+81% YoY); Auvelity $80.4M (+113%); net loss $64.6M","bullets":["Total net product revenue $104.8M, up 81% YoY; Auvelity $80.4M (+113%), Sunosi $24.4M (+21%).","Net loss $64.6M ($1.34 loss per share); cash and equivalents $327.3M at Sept 30, 2024.","Auvelity sales force to expand to ~300 reps in Q1 2025 due to strong demand growth.","AXS-07 migraine NDA resubmission accepted with PDUFA goal date January 31, 2025.","Topline results for AXS-05 (AD agitation) and AXS-12 (narcolepsy) on track for Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124546","json":"https://secwatch.observer/filing/0000950170-24-124546.json","markdown":"https://secwatch.observer/filing/0000950170-24-124546.md","text":"https://secwatch.observer/filing/0000950170-24-124546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/0000950170-24-124546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:54:28.008970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}